Howard E Gendelman

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6142967/publications.pdf

Version: 2024-02-01

410 papers	26,175 citations	4658 85 h-index	10734 138 g-index
429 all docs	429 docs citations	429 times ranked	24415 citing authors

#	Article	IF	Citations
1	A call for transparent reporting to optimize the predictive value of preclinical research. Nature, 2012, 490, 187-191.	27.8	1,055
2	Diagnostics for SARS-CoV-2 infections. Nature Materials, 2021, 20, 593-605.	27.5	533
3	Dementia Associated with the Acquired Immunodeficiency Syndrome. New England Journal of Medicine, 1995, 332, 934-940.	27.0	476
4	Selective inhibition of NF-ÎºB activation prevents dopaminergic neuronal loss in a mouse model of Parkinson's disease. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 18754-18759.	7.1	391
5	The Natural History, Pathobiology, and Clinical Manifestations of SARS-CoV-2 Infections. Journal of NeuroImmune Pharmacology, 2020, 15, 359-386.	4.1	391
6	Human immunodeficiency virus type 1 infection of the nervous system: Pathogenetic mechanisms. Annals of Neurology, 1993, 33, 429-436.	5.3	377
7	Oxidative Stress and the Pathogenesis of Neurodegenerative Disorders. International Review of Neurobiology, 2007, 82, 297-325.	2.0	350
8	Interferon-Î³ and Tumor Necrosis Factor-Î± Regulate Amyloid-Î² Plaque Deposition and Î²-Secretase Expression in Swedish Mutant APP Transgenic Mice. American Journal of Pathology, 2007, 170, 680-692.	3.8	348
9	Regulatory T Cells Attenuate Th17 Cell-Mediated Nigrostriatal Dopaminergic Neurodegeneration in a Model of Parkinsonâ€™s Disease. Journal of Immunology, 2010, 184, 2261-2271.	0.8	346
10	Neuroprotective activities of CD4+CD25+ regulatory T cells in an animal model of Parkinsonâ€™s disease. Journal of Leukocyte Biology, 2007, 82, 1083-1094.	3.3	323
11	Nitrated Î±â€“Synuclein Immunity Accelerates Degeneration of Nigral Dopaminergic Neurons. PLoS ONE, 2008, 3, e1376.	2.5	311
12	Neuroinflammation, oxidative stress, and the pathogenesis of Parkinsonâ€™s disease. Clinical Neuroscience Research, 2006, 6, 261-281.	0.8	305
13	Intracellular CXCR4 signaling, neuronal apoptosis and neuropathogenic mechanisms of HIV-1-associated dementia. Journal of Neuroimmunology, 1999, 98, 185-200.	2.3	299
14	Therapeutic immunization protects dopaminergic neurons in a mouse model of Parkinson's disease. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 9435-9440.	7.1	299
15	Role of Mononuclear Phagocytes in the Pathogenesis of Human Immunodeficiency Virus Infection. Annual Review of Immunology, 1990, 8, 169-194.	21.8	279
16	Cell-mediated drug delivery. Expert Opinion on Drug Delivery, 2011, 8, 415-433.	5.0	274
17	Microglial and Astrocyte Chemokines Regulate Monocyte Migration through the Blood-Brain Barrier in Human Immunodeficiency Virus-1 Encephalitis. American Journal of Pathology, 1999, 155, 1599-1611.	3.8	266
18	CD4+ Regulatory and Effector/Memory T Cell Subsets Profile Motor Dysfunction in Parkinsonâ€™s Disease. Journal of NeuroImmune Pharmacology, 2012, 7, 927-938.	4.1	255

#	Article	IF	Citations
19	The neuropathogenesis of HIV-1 infection. Journal of Leukocyte Biology, 1994, 56, 389-398.	3.3	247
20	Development of a macrophage-based nanoparticle platform for antiretroviral drug delivery. Blood, 2006, 108, 2827-2835.	1.4	241
21	Nanotechnology: A Focus on Nanoparticles as a Drug Delivery System. Journal of NeuroImmune Pharmacology, 2006, 1, 340-350.	4.1	222
22	Sequential LASER ART and CRISPR Treatments Eliminate HIV-1 in a Subset of Infected Humanized Mice. Nature Communications, 2019, 10, 2753.	12.8	222
23	Inflammation and Adaptive Immunity in Parkinson's Disease. Cold Spring Harbor Perspectives in Medicine, 2012, 2, a009381-a009381.	6.2	221
24	Macrophage Delivery of Nanoformulated Antiretroviral Drug to the Brain in a Murine Model of NeuroAIDS. Journal of Immunology, 2009, 183, 661-669.	0.8	211
25	HIV-1 gp120 Compromises Bloodâ€“Brain Barrier Integrity and Enhance Monocyte Migration across Bloodâ€“Brain Barrier: Implication for Viral Neuropathogenesis. Journal of Cerebral Blood Flow and Metabolism, 2007, 27, 123-134.	4.3	202
26	Methamphetamine-Associated Psychosis. Journal of NeuroImmune Pharmacology, 2012, 7, 113-139.	4.1	202
27	A Functional Transsulfuration Pathway in the Brain Links to Glutathione Homeostasis. Journal of Biological Chemistry, 2006, 281, 35785-35793.	3.4	198
28	Biochemical and Biologic Characterization of Exosomes and Microvesicles as Facilitators of HIV-1 Infection in Macrophages. Journal of Immunology, 2012, 189, 744-754.	0.8	198
29	Nitrated alphaâ€synucleinâ€activated microglial profiling for Parkinsonâ€™s disease. Journal of Neurochemistry, 2008, 104, 1504-1525.	3.9	195
30	CNS expression of antiâ€inflammatory cytokine interleukinâ€4 attenuates Alzheimer's diseaseâ€like pathogenesis in APP+PS1 bigenic mice. FASEB Journal, 2010, 24, 3093-3102.	0.5	187
31	Neuronal Fractalkine Expression in HIV-1 Encephalitis: Roles for Macrophage Recruitment and Neuroprotection in the Central Nervous System. Journal of Immunology, 2000, 164, 1333-1339.	0.8	186
32	A Macrophageâ€'Nanozyme Delivery System for Parkinson's Disease. Bioconjugate Chemistry, 2007, 18, 1498-1506.	3.6	177
33	Nitrated Î±-Synuclein-Induced Alterations in Microglial Immunity Are Regulated by CD4+ T Cell Subsets. Journal of Immunology, 2009, 182, 4137-4149.	0.8	177
34	Adaptive Immune Neuroprotection in G93A-SOD1 Amyotrophic Lateral Sclerosis Mice. PLoS ONE, 2008, 3, e2740.	2.5	174
35	Macrophages and the human immunodeficiency virus. Trends in Immunology, 1990, 11, 217-223.	7.5	173
36	Suppression of Inflammatory Neurotoxins by Highly Active Antiretroviral Therapy in Human Immunodeficiency Virusâ€Associated Dementia. Journal of Infectious Diseases, 1998, 178, 1000-1007.	4.0	169

#	Article	IF	Citations
37	Simvastatin Inhibits the Activation of p21^{ras}and Prevents the Loss of Dopaminergic Neurons in a Mouse Model of Parkinson's Disease. Journal of Neuroscience, 2009, 29, 13543-13556.	3.6	156
38	Macrophage delivery of therapeutic nanozymes in a murine model of Parkinsonâ€™s disease. Nanomedicine, 2010, 5, 379-396.	3.3	154
39	Mononuclear phagocyte immunity and the neuropathogenesis of HIV-1 infection. Journal of Leukocyte Biology, 2003, 74, 691-701.	3.3	152
40	Role of the Î²-Chemokine Receptors CCR3 and CCR5 in Human Immunodeficiency Virus Type 1 Infection of Monocytes and Microglia. Journal of Virology, 1998, 72, 3351-3361.	3.4	146
41	Inhibition of indoleamine 2,3-dioxygenase (IDO) enhances elimination of virus-infected macrophages in an animal model of HIV-1 encephalitis. Blood, 2005, 106, 2382-2390.	1.4	144
42	Effects of pluronic and doxorubicin on drug uptake, cellular metabolism, apoptosis and tumor inhibition in animal models of MDR cancers. Journal of Controlled Release, 2010, 143, 290-301.	9.9	142
43	HIV-1â€“Associated Dementia: A Metabolic Encephalopathy Perpetrated by Virus-Infected and Immune-Competent Mononuclear Phagocytes. Journal of Acquired Immune Deficiency Syndromes (1999), 2002, 31, S43-S54.	2.1	134
44	Alzheimerâ€™s disease brain-derived extracellular vesicles spread tau pathology in interneurons. Brain, 2021, 144, 288-309.	7.6	132
45	Overexpression of Monocyte Chemotactic Protein-1/CCL2 in Î²-Amyloid Precursor Protein Transgenic Mice Show Accelerated Diffuse Î²-Amyloid Deposition. American Journal of Pathology, 2005, 166, 1475-1485.	3.8	130
46	Human Immunodeficiency Virus Type 1 Pathobiology Studied in Humanized BALB/c-Rag2 â^'/â^' Î³ c â^'/â^' Mice. Journal of Virology, 2007, 81, 2700-2712.	3.4	130
47	STAT1 signaling modulates HIV-1â€“induced inflammatory responses and leukocyte transmigration across the blood-brain barrier. Blood, 2008, 111, 2062-2072.	1.4	130
48	Lymphotropic Virions Affect Chemokine Receptor-Mediated Neural Signaling and Apoptosis: Implications for Human Immunodeficiency Virus Type 1-Associated Dementia. Journal of Virology, 1999, 73, 8256-8267.	3.4	125
49	Specific Transfection of Inflamed Brain by Macrophages: A New Therapeutic Strategy for Neurodegenerative Diseases. PLoS ONE, 2013, 8, e61852.	2.5	124
50	Interferons in the Persistence, Pathogenesis, and Treatment of HIV Infection. AIDS Research and Human Retroviruses, 1992, 8, 199-207.	1.1	121
51	An analysis of HIV-1-associated inflammatory products in brain tissue of humans and SCID mice with HIV-1 encephalitis. Journal of NeuroVirology, 1997, 3, 401-416.	2.1	121
52	Long-acting nanoformulated antiretroviral therapy elicits potent antiretroviral and neuroprotective responses in HIV-1-infected humanized mice. Aids, 2012, 26, 2135-2144.	2.2	121
53	NanoART synthesis, characterization, uptake, release and toxicology for human monocyteâ€“macrophage drug delivery. Nanomedicine, 2009, 4, 903-917.	3.3	116
54	Facilitated Monocyte-Macrophage Uptake and Tissue Distribution of Superparmagnetic Iron-Oxide Nanoparticles. PLoS ONE, 2009, 4, e4343.	2.5	116

#	Article	IF	Citations
55	Ion channel blockade attenuates aggregated alpha synuclein induction of microglial reactive oxygen species: relevance for the pathogenesis of Parkinson's disease. Journal of Neurochemistry, 2007, 100, 503-519.	3.9	115
56	Molecular mechanisms involving sigma receptorâ€“mediated induction of MCP-1: implication for increased monocyte transmigration. Blood, 2010, 115, 4951-4962.	1.4	115
57	Quantitative diffusion tensor imaging detects dopaminergic neuronal degeneration in a murine model of Parkinsonâ€™s disease. Neurobiology of Disease, 2007, 26, 590-596.	4.4	114
58	Innate and Adaptive Immunity for the Pathobiology of Parkinson's Disease. Antioxidants and Redox Signaling, 2009, 11, 2151-2166.	5.4	114
59	Neural Immunity: Friend or Foe?. Journal of NeuroVirology, 2002, 8, 474-479.	2.1	113
60	Neuroprotective Activities of Sodium Valproate in a Murine Model of Human Immunodeficiency Virus-1 Encephalitis. Journal of Neuroscience, 2003, 23, 9162-9170.	3.6	113
61	Nitrated Alpha-Synuclein and Microglial Neuroregulatory Activities. Journal of NeuroImmune Pharmacology, 2008, 3, 59-74.	4.1	113
62	Macrophages as Susceptible Targets for HIV Infection, Persistent Viral Reservoirs in Tissue, and Key Immunoregulatory Cells that Control Levels of Virus Replication and Extent of Disease. AIDS Research and Human Retroviruses, 1990, 6, 967-971.	1.1	112
63	NanoART, neuroAIDS and CNS drug delivery. Nanomedicine, 2009, 4, 557-574.	3.3	112
64	Unraveling the neuroimmune mechanisms for the HIV-1-associated cognitive/motor complex. Trends in Immunology, 1995, 16, 441-448.	7.5	110
65	A Coat of Many Colors: Neuroimmune Crosstalk in Human Immunodeficiency Virus Infection. Neuron, 2009, 64, 133-145.	8.1	110
66	Loss of Neuronal Integrity during Progressive HIV-1 Infection of Humanized Mice. Journal of Neuroscience, 2011, 31, 3148-3157.	3.6	110
67	Analyses of nanoformulated antiretroviral drug charge, size, shape and content for uptake, drug release and antiviral activities in human monocyte-derived macrophages. Journal of Controlled Release, 2011, 150, 204-211.	9.9	107
68	Sodium Phenylbutyrate Controls Neuroinflammatory and Antioxidant Activities and Protects Dopaminergic Neurons in Mouse Models of Parkinsonâ€™s Disease. PLoS ONE, 2012, 7, e38113.	2.5	106
69	Proteomic and biological profiling of extracellular vesicles from Alzheimer's disease human brain tissues. Alzheimer's and Dementia, 2020, 16, 896-907.	0.8	105
70	Cell Delivery of Therapeutic Nanoparticles. Progress in Molecular Biology and Translational Science, 2011, 104, 563-601.	1.7	101
71	Creation of a long-acting nanoformulated dolutegravir. Nature Communications, 2018, 9, 443.	12.8	101
72	CCL2 Accelerates Microglia-Mediated AÎ² Oligomer Formation and Progression of Neurocognitive Dysfunction. PLoS ONE, 2009, 4, e6197.	2.5	100

#	Article	IF	Citations
73	Nanoneuromedicines for degenerative, inflammatory, and infectious nervous system diseases. Nanomedicine: Nanotechnology, Biology, and Medicine, 2015, 11, 751-767.	3.3	98
74	Evaluation of the safety and immunomodulatory effects of sargramostim in a randomized, double-blind phase 1 clinical Parkinsonâ€™s disease trial. Npj Parkinson's Disease, 2017, 3, 10.	5.3	98
75	Nanoformulated Antiretroviral Drug Combinations Extend Drug Release and Antiretroviral Responses in HIV-1-Infected Macrophages: Implications for NeuroAIDS Therapeutics. Journal of NeuroImmune Pharmacology, 2010, 5, 592-601.	4.1	97
76	Cerebrospinal Fluid Proteomic Profiling of HIV-1-Infected Patients with Cognitive Impairment. Journal of Proteome Research, 2007, 6, 4189-4199.	3.7	95
77	Links between Progressive HIV-1 Infection of Humanized Mice and Viral Neuropathogenesis. American Journal of Pathology, 2010, 177, 2938-2949.	3.8	94
78	A mature macrophage is a principal HIV-1 cellular reservoir in humanized mice after treatment with long acting antiretroviral therapy. Retrovirology, 2017, 14, 17.	2.0	94
79	Human Immunodeficiency Virus Neurotropism: an Analysis of Viral Replication and Cytopathicity for Divergent Strains in Monocytes and Microglia. Journal of Virology, 1998, 72, 3340-3350.	3.4	94
80	Regulation of tissue inhibitor of metalloproteinase-1 by astrocytes: Links to HIV-1 dementia. Glia, 2003, 44, 47-56.	4.9	93
81	HIV-1-infected and/or immune activated macrophages regulate astrocyte SDF-1 production through IL-1Î². Glia, 2006, 54, 619-629.	4.9	92
82	Selection of a fixative for identifying T cell subsets, B cells, and macrophages in paraffin-embedded mouse spleen. Journal of Immunological Methods, 1983, 65, 137-145.	1.4	90
83	Laboratory investigations for the morphologic, pharmacokinetic, and anti-retroviral properties of indinavir nanoparticles in human monocyte-derived macrophages. Virology, 2007, 358, 148-158.	2.4	90
84	CD4+ T cells from Copolymer-1 immunized mice protect dopaminergic neurons in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. Journal of Neuroimmunology, 2007, 183, 60-68.	2.3	90
85	Lithium therapy for human immunodeficiency virus type 1â€“associated neurocognitive impairment. Journal of NeuroVirology, 2009, 15, 176-186.	2.1	90
86	GM-CSF induces neuroprotective and anti-inflammatory responses in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine intoxicated mice. Journal of Neuroimmunology, 2013, 265, 1-10.	2.3	90
87	Cytokine-Stimulated, But Not HIV-Infected, Human Monocyte-Derived Macrophages Produce Neurotoxic Levels of <scp>l</scp>-Cysteine. Journal of Immunology, 2000, 164, 4265-4270.	0.8	89
88	Metabolic drift in the aging brain. Aging, 2016, 8, 1000-1020.	3.1	89
89	Tracking superparamagnetic iron oxide labeled monocytes in brain by high-field magnetic resonance imaging. Journal of Neuroscience Research, 2003, 73, 284-295.	2.9	87
90	Plasma Levels of Soluble CD14 and Tumor Necrosis Factorâ€Î± Type II Receptor Correlate with Cognitive Dysfunction during Human Immunodeficiency Virus Type 1 Infection. Journal of Infectious Diseases, 2001, 184, 699-706.	4.0	85

#	Article	IF	Citations
91	Long-acting parenteral nanoformulated antiretroviral therapy: interest and attitudes of HIV-infected patients. Nanomedicine, 2013, 8, 1807-1813.	3.3	85
92	Neuronal injury regulates fractalkine: relevance for HIV-1 associated dementia. Journal of Neuroimmunology, 2003, 138, 144-155.	2.3	83
93	Macrophage folate receptor-targeted antiretroviral therapy facilitates drug entry, retention, antiretroviral activities and biodistribution for reduction of human immunodeficiency virus infections. Nanomedicine: Nanotechnology, Biology, and Medicine, 2013, 9, 1263-1273.	3.3	83
94	Mononuclear Phagocyte Differentiation, Activation, and Viral Infection Regulate Matrix Metalloproteinase Expression: Implications for Human Immunodeficiency Virus Type 1-Associated Dementia. Journal of Virology, 2001, 75, 6572-6583.	3.4	82
95	Neuromodulatory Activities of CD4+CD25+ Regulatory T Cells in a Murine Model of HIV-1-Associated Neurodegeneration. Journal of Immunology, 2009, 182, 3855-3865.	0.8	82
96	CD8+ Cell Depletion Accelerates HIV-1 Immunopathology in Humanized Mice. Journal of Immunology, 2010, 184, 7082-7091.	0.8	80
97	Proteomic Studies of Nitrated Alpha-Synuclein Microglia Regulation by CD4+CD25+ T Cells. Journal of Proteome Research, 2009, 8, 3497-3511.	3.7	78
98	HIV-1 neuroimmunity in the era of antiretroviral therapy. Neurobiology of Disease, 2010, 37, 542-548.	4.4	78
99	Macrophages offer a paradigm switch for CNS delivery of therapeutic proteins. Nanomedicine, 2014, 9, 1403-1422.	3.3	78
100	SARS-CoV-2 Infection Leads to Neurological Dysfunction. Journal of NeuroImmune Pharmacology, 2020, 15, 167-173.	4.1	78
101	A double labeling technique for performing immunocytochemistry and in situ hybridization in virus infected cell cultures and tissues. Journal of Virological Methods, 1985, 11, 93-103.	2.1	77
102	Creation of a nanoformulated cabotegravir prodrug with improved antiretroviral profiles. Biomaterials, 2018, 151, 53-65.	11.4	77
103	Insights into the neurodegenerative process of Alzheimer's disease: a role for mononuclear phagocyte-associated inflammation and neurotoxicity. Journal of Leukocyte Biology, 1999, 65, 416-427.	3.3	76
104	Quantitative 1H Magnetic Resonance Spectroscopic Imaging Determines Therapeutic Immunization Efficacy in an Animal Model of Parkinson's Disease. Journal of Neuroscience, 2005, 25, 1691-1700.	3.6	76
105	Development of mannose-anchored thiolated amphotericin B nanocarriers for treatment of visceral leishmaniasis. Nanomedicine, 2017, 12, 99-115.	3.3	76
106	Human Immunodeficiency Virus type 1 Endocytic Trafficking Through Macrophage Bridging Conduits Facilitates Spread of Infection. Journal of NeuroImmune Pharmacology, 2011, 6, 658-675.	4.1	75
107	Development of HIV Reservoir Targeted Long Acting Nanoformulated Antiretroviral Therapies. Current Medicinal Chemistry, 2014, 21, 4186-4198.	2.4	75
108	Impaired Spatial Cognition and Synaptic Potentiation in a Murine Model of Human Immunodeficiency Virus Type 1 Encephalitis. Journal of Neuroscience, 2002, 22, 2096-2105.	3.6	73

#	Article	IF	Citations
109	The HIV-1 associated dementia complex. Current Opinion in Neurology, 1997, 10, 319-326.	3.6	72
110	Neuroprotective Mechanisms of Lithium in Murine Human Immunodeficiency Virus-1 Encephalitis. Journal of Neuroscience, 2005, 25, 8375-8385.	3.6	72
111	Investigating the human immunodeficiency virus type 1-infected monocyte-derived macrophage secretome. Virology, 2007, 363, 198-209.	2.4	72
112	Hypersynchrony despite pathologically reduced beta oscillations in patients with Parkinson's disease: a pharmaco-magnetoencephalography study. Journal of Neurophysiology, 2014, 112, 1739-1747.	1.8	72
113	Memantine Protects Hippocampal Neuronal Function in Murine Human Immunodeficiency Virus Type 1 Encephalitis. Journal of Neuroscience, 2004, 24, 7194-7198.	3.6	71
114	Preclinical Pharmacokinetics and Tissue Distribution of Long-Acting Nanoformulated Antiretroviral Therapy. Antimicrobial Agents and Chemotherapy, 2013, 57, 3110-3120.	3.2	70
115	The Human Immunodeficiency Virus Long Terminal Repeat Is Preferentially Expressed in Langerhans Cells in Transgenic Mice. AIDS Research and Human Retroviruses, 1989, 5, 421-430.	1.1	69
116	Generation of Cytotoxic T Cells Against Virus-Infected Human Brain Macrophages in a Murine Model of HIV-1 Encephalitis. Journal of Immunology, 2002, 168, 3941-3949.	0.8	69
117	Macrophage Bridging Conduit Trafficking of HIV-1 Through the Endoplasmic Reticulum and Golgi Network. Journal of Proteome Research, 2011, 10, 3225-3238.	3.7	68
118	Selective VIP Receptor Agonists Facilitate Immune Transformation for Dopaminergic Neuroprotection in MPTP-Intoxicated Mice. Journal of Neuroscience, 2015, 35, 16463-16478.	3.6	68
119	Novel Delivery System Enhances Efficacy of Antiretroviral Therapy in Animal Model for HIV-1 Encephalitis. Journal of Cerebral Blood Flow and Metabolism, 2007, 27, 1033-1042.	4.3	67
120	Cell-mediated transfer of catalase nanoparticles from macrophages to brain endothelial, glial and neuronal cells. Nanomedicine, 2011, 6, 1215-1230.	3.3	67
121	CCL2 affects Î²-amyloidosis and progressive neurocognitive dysfunction in a mouse model of Alzheimer's disease. Neurobiology of Aging, 2013, 34, 1060-1068.	3.1	67
122	Mononuclear phagocytes in the pathogenesis of neurodegenerative diseases. Neurotoxicity Research, 2005, 8, 25-50.	2.7	66
123	Rodent models for HIV-associated neurocognitive disorders. Trends in Neurosciences, 2012, 35, 197-208.	8.6	66
124	A year-long extended release nanoformulated cabotegravir prodrug. Nature Materials, 2020, 19, 910-920.	27.5	66
125	Nanocarrier vaccines for SARS-CoV-2. Advanced Drug Delivery Reviews, 2021, 171, 215-239.	13.7	66
126	Dual destructive and protective roles of adaptive immunity in neurodegenerative disorders. Translational Neurodegeneration, 2014, 3, 25.	8.0	65

#	Article	IF	Citations
127	Brain Region Mapping Using Global Metabolomics. Chemistry and Biology, 2014, 21, 1575-1584.	6.0	65
128	Quantitative magnetic resonance and SPECT imaging for macrophage tissue migration and nanoformulated drug delivery. Journal of Leukocyte Biology, 2006, 80, 1165-1174.	3.3	64
129	Genomic and proteomic microglial profiling: pathways for neuroprotective inflammatory responses following nerve fragment clearance and activation. Journal of Neurochemistry, 2007, 102, 627-645.	3.9	64
130	Restriction of HIV Replication in Infected T Cells and Monocytes by Interferon-Î±. AIDS Research and Human Retroviruses, 1990, 6, 1045-1049.	1.1	63
131	Debate: â€œIs Increasing Neuroinflammation Beneficial for Neural Repair?â€. Journal of NeuroImmune Pharmacology, 2006, 1, 195-211.	4.1	63
132	HIV-1 infected monocyte-derived macrophages affect the human brain microvascular endothelial cell proteome: New insights into bloodâ€“brain barrier dysfunction for HIV-1-associated dementia. Journal of Neuroimmunology, 2007, 185, 37-46.	2.3	63
133	Neurotheranostics as personalized medicines. Advanced Drug Delivery Reviews, 2019, 148, 252-289.	13.7	63
134	T cell independent mechanism for copolymerâ€1â€induced neuroprotection. European Journal of Immunology, 2007, 37, 3143-3154.	2.9	62
135	AAV1/2-mediated CNS Gene Delivery of Dominant-negative CCL2 Mutant Suppresses Gliosis, Î²-amyloidosis, and Learning Impairment of APP/PS1 Mice. Molecular Therapy, 2009, 17, 803-809.	8.2	62
136	Macrophage endocytic trafficking of antiretroviral nanoparticles. Nanomedicine, 2011, 6, 975-994.	3.3	62
137	Pharmacodynamic and Antiretroviral Activities of Combination Nanoformulated Antiretrovirals in HIV-1â€“Infected Human Peripheral Blood Lymphocyteâ€“Reconstituted Mice. Journal of Infectious Diseases, 2012, 206, 1577-1588.	4.0	62
138	Neurodegenerative disorders and nanoformulated drug development. Nanomedicine, 2009, 4, 541-555.	3.3	61
139	Prospective Utility of Cerebral Proton Magnetic Resonance Spectroscopy in Monitoring HIV Infection and Its Associated Neurological Impairment. AIDS Research and Human Retroviruses, 1994, 10, 977-982.	1.1	60
140	An experimental model system for HIV-1-induced brain injury. Advances in Neuroimmunology, 1994, 4, 189-193.	1.8	59
141	HIV-1 cellular and tissue replication patterns in infected humanized mice. Scientific Reports, 2016, 6, 23513.	3.3	59
142	Infection of Human Gastrointestinal Cells by HIV-1. AIDS Research and Human Retroviruses, 1990, 6, 1409-1415.	1.1	58
143	Inhibition of long-term potentiation by interleukin-8: Implications for human immunodeficiency virus-1-associated dementia. Journal of Neuroscience Research, 2003, 71, 600-607.	2.9	58
144	Active Targeted Macrophage-mediated Delivery of Catalase to Affected Brain Regions in Models of Parkinson?s Disease. Journal of Nanomedicine & Nanotechnology, 2011, 01, .	1.1	58

#	Article	IF	Citations
145	Bench-to-bedside translation of magnetic nanoparticles. Nanomedicine, 2014, 9, 501-516.	3.3	58
146	Pharmacodynamics of long-acting folic acid-receptor targeted ritonavir-boosted atazanavir nanoformulations. Biomaterials, 2015, 41, 141-150.	11.4	58
147	CSF proteomic fingerprints for HIV-associated cognitive impairment. Journal of Neuroimmunology, 2007, 192, 157-170.	2.3	57
148	Harnessing regulatory T cell neuroprotective activities for treatment of neurodegenerative disorders. Molecular Neurodegeneration, 2020, 15, 32.	10.8	57
149	Immunotherapy for Parkinsonâ€™s disease. Neurobiology of Disease, 2020, 137, 104760.	4.4	57
150	TNF-related apoptosis-inducing ligand mediates human neuronal apoptosis: links to HIV-1-associated dementia. Journal of Neuroimmunology, 2004, 148, 127-139.	2.3	55
151	Development of laboratory and animal model systems for HIV-1 encephalitis and its associated dementia. Journal of Leukocyte Biology, 1997, 62, 100-106.	3.3	54
152	Macrophage-induced inflammation affects hippocampal plasticity and neuronal development in a murine model of HIV-1 encephalitis. Glia, 2005, 52, 344-353.	4.9	54
153	Nano-enabled delivery of diverse payloads across complex biological barriers. Journal of Controlled Release, 2015, 219, 548-559.	9.9	54
154	Long-acting slow effective release antiretroviral therapy. Expert Opinion on Drug Delivery, 2017, 14, 1281-1291.	5.0	53
155	Granulocyte-macrophage colony-stimulating factor neuroprotective activities in Alzheimerâ€™s disease mice. Journal of Neuroimmunology, 2018, 319, 80-92.	2.3	53
156	Human Interleukin-34 facilitates microglia-like cell differentiation and persistent HIV-1 infection in humanized mice. Molecular Neurodegeneration, 2019, 14, 12.	10.8	53
157	The cellular immunology of multiple sclerosis. Journal of Leukocyte Biology, 1999, 65, 444-452.	3.3	52
158	Associations between brain microstructures, metabolites, and cognitive deficits during chronic HIV-1 infection of humanized mice. Molecular Neurodegeneration, 2014, 9, 58.	10.8	52
159	Neuroregulatory Events Follow Adaptive Immune-Mediated Elimination of HIV-1-Infected Macrophages: Studies in a Murine Model of Viral Encephalitis. Journal of Immunology, 2004, 172, 7610-7617.	0.8	51
160	The cortical signature of symptom laterality in Parkinson's disease. NeuroImage: Clinical, 2017, 14, 433-440.	2.7	51
161	Cathepsin B Improves ÃŸ-Amyloidosis and Learning and Memory in Models of Alzheimerâ€™s Disease. Journal of NeuroImmune Pharmacology, 2017, 12, 340-352.	4.1	51
162	EcoHIV infection of mice establishes latent viral reservoirs in T cells and active viral reservoirs in macrophages that are sufficient for induction of neurocognitive impairment. PLoS Pathogens, 2018, 14, e1007061.	4.7	51

#	Article	IF	Citations
163	Surface-engineered multimodal magnetic nanoparticles to manage CNS diseases. Drug Discovery Today, 2019, 24, 873-882.	6.4	51
164	Comprehensive bioimaging with fluorinated nanoparticles using breathable liquids. Nature Communications, 2015, 6, 5998.	12.8	50
165	No Direct Neuronotoxicity by HIV-1 Virions or Culture Fluids from HIV-1-Infected T Cells or Monocytes. AIDS Research and Human Retroviruses, 1992, 8, 495-503.	1.1	49
166	C1qâ€“calreticulin induced oxidative neurotoxicity: relevance for the neuropathogenesis of Alzheimer's disease. Journal of Neuroimmunology, 2003, 135, 62-71.	2.3	48
167	CD 4+ T cells in the pathobiology of neurodegenerative disorders. Journal of Neuroimmunology, 2009, 211, 3-15.	2.3	48
168	Immunoregulation of a CB2 Receptor Agonist in a Murine Model of NeuroAIDS. Journal of NeuroImmune Pharmacology, 2010, 5, 456-468.	4.1	48
169	Mononuclear phagocyte intercellular crosstalk facilitates transmission of cell-targeted nanoformulated antiretroviral drugs to human brain endothelial cells. International Journal of Nanomedicine, 2012, 7, 2373.	6.7	48
170	Endosomal Trafficking of Nanoformulated Antiretroviral Therapy Facilitates Drug Particle Carriage and HIV Clearance. Journal of Virology, 2014, 88, 9504-9513.	3.4	48
171	CD4+ effector T cells accelerate Alzheimerâ€™s disease in mice. Journal of Neuroinflammation, 2021, 18, 272.	7.2	48
172	Neuroprotective Activities of CEP-1347 in Models of NeuroAIDS. Journal of Immunology, 2010, 184, 746-756.	0.8	47
173	Formulation design facilitates magnetic nanoparticle delivery to diseased cells and tissues. Nanomedicine, 2014, 9, 469-485.	3.3	47
174	Cytoskeletal Protein Transformation in HIV-1-Infected Macrophage Giant Cells. Journal of Immunology, 2007, 178, 6404-6415.	0.8	46
175	Enabling nanomaterial, nanofabrication and cellular technologies for nanoneuromedicines. Nanomedicine: Nanotechnology, Biology, and Medicine, 2015, 11, 715-729.	3.3	46
176	Immunomodulation as a neuroprotective and therapeutic strategy for Parkinson's disease. Current Opinion in Pharmacology, 2016, 26, 87-95.	3.5	46
177	Proteomic Modeling for HIV-1 Infected Microglia-Astrocyte Crosstalk. PLoS ONE, 2008, 3, e2507.	2.5	46
178	Bridge between neuroimmunity and traumatic brain injury. Current Pharmaceutical Design, 2014, 20, 4284-98.	1.9	45
179	Cellular and viral determinants that regulate HIV-1 infection in macrophages. Journal of Leukocyte Biology, 1994, 56, 278-288.	3.3	44
180	Regulation of Human Immunodeficiency Virus Type 1 Infection, Î²-Chemokine Production, and CCR5 Expression in CD40L-Stimulated Macrophages: Immune Control of Viral Entry. Journal of Virology, 2001, 75, 4308-4320.	3.4	44

#	Article	IF	Citations
181	Human Dendritic Cells Transduced with Herpes Simplex Virus Amplicons Encoding Human Immunodeficiency Virus Type 1 (HIV-1) gp120 Elicit Adaptive Immune Responses from Human Cells Engrafted into NOD/SCID Mice and Confer Partial Protection against HIV-1 Challenge. Journal of Virology, 2005, 79, 2124-2132.	3.4	44
182	Therapeutic immunization with a glatiramer acetate derivative does not alter survival in G93A and G37R SOD1 mouse models of familial ALS. Neurobiology of Disease, 2007, 26, 146-152.	4.4	44
183	HIV-1-Infected Astrocytes and the Microglial Proteome. Journal of NeuroImmune Pharmacology, 2008, 3, 173-186.	4.1	44
184	Monocyte Chemotactic Protein-1 Regulates Voltage-Gated K+ Channels and Macrophage Transmigration. Journal of NeuroImmune Pharmacology, 2009, 4, 47-59.	4.1	44
185	Autophagy facilitates macrophage depots of sustained-release nanoformulated antiretroviral drugs. Journal of Clinical Investigation, 2017, 127, 857-873.	8.2	44
186	The regulation of alpha chemokines during HIV-1 infection and leukocyte activation: relevance for HIV-1-associated dementia. Journal of Neuroimmunology, 2001, 120, 112-128.	2.3	43
187	Inhibition of human immunodeficiency virus infection in monocytes by monoclonal antibodies against leukocyte adhesion molecules. Immunology Letters, 1991, 30, 219-227.	2.5	42
188	HIV-Associated Dementia: New Insights into Disease Pathogenesis and Therapeutic Interventions. AIDS Patient Care and STDs, 1999, 13, 153-163.	2.5	42
189	Neuroprotective activities of regulatory T cells. Trends in Molecular Medicine, 2011, 17, 687-688.	6.7	41
190	Quiet connections: Reduced frontoâ€temporal connectivity in nondemented Parkinson's Disease during working memory encoding. Human Brain Mapping, 2016, 37, 3224-3235.	3.6	41
191	Development and characterization of a long-acting nanoformulated abacavir prodrug. Nanomedicine, 2016, 11, 1913-1927.	3.3	41
192	Creation of a Long-Acting Nanoformulated 2â€²,3â€²-Dideoxy-3â€²-Thiacytidine. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 74, e75-e83.	2.1	41
193	Soluble HIV-1 infected macrophage secretory products mediate blockade of long-term potentiation: a mechanism for cognitive dysfunction in HIV-1-associated dementia. Journal of NeuroVirology, 1999, 5, 519-528.	2.1	40
194	Multimodal Theranostic Nanoformulations Permit Magnetic Resonance Bioimaging of Antiretroviral Drug Particle Tissue-Cell Biodistribution. Theranostics, 2018, 8, 256-276.	10.0	40
195	The regulation of quinolinic acid in human immunodeficiency virus-infected monocytes. Journal of NeuroVirology, 1996, 2, 111-117.	2.1	39
196	Glycogen Synthase Kinase 3 Beta (GSK-3Î²) as a Therapeutic Target in NeuroAIDS. Journal of NeuroImmune Pharmacology, 2007, 2, 93-96.	4.1	39
197	Longâ€acting antituberculous therapeutic nanoparticles target macrophage endosomes. FASEB Journal, 2014, 28, 5071-5082.	0.5	39
198	An interactive cluster heat map to visualize and explore multidimensional metabolomic data. Metabolomics, 2015, 11, 1029-1034.	3.0	39

#	Article	IF	Citations
199	Tolerogenic bone marrow-derived dendritic cells induce neuroprotective regulatory T cells in a model of Parkinsonâ€™s disease. Molecular Neurodegeneration, 2018, 13, 26.	10.8	39
200	The development of animal model systems for HIV-1 encephalitis and its associated dementia. Journal of NeuroVirology, 1995, 1, 229-243.	2.1	38
201	A model of nitric oxide induced Î±-synuclein misfolding in Parkinson's disease. Neuroscience Letters, 2012, 523, 167-173.	2.1	38
202	Comparative manufacture and cell-based delivery of antiretroviral nanoformulations. International Journal of Nanomedicine, 2011, 6, 3393.	6.7	37
203	HIV-1 infected and immune competent mononuclear phagocytes induce quantitative alterations in neuronal dendritic arbor: Relevance for HIV-1-associated dementia. Neurotoxicity Research, 2001, 3, 443-459.	2.7	36
204	Advances in Neuroimaging for HIV-1 Associated Neurological Dysfunction: Clues to the Diagnosis, Pathogenesis and Therapeutic Monitoring. Current HIV Research, 2004, 2, 61-78.	0.5	36
205	Copolymer-1 Induces Adaptive Immune Anti-inflammatory Glial and Neuroprotective Responses in a Murine Model of HIV-1 Encephalitis. Journal of Immunology, 2007, 179, 4345-4356.	0.8	36
206	Adaptive immune regulation of glial homeostasis as an immunization strategy for neurodegenerative diseases. Journal of Neurochemistry, 2010, 114, 1261-1276.	3.9	36
207	A Perspective on Roles Played by Innate and Adaptive Immunity in the Pathobiology of Neurodegenerative Disorders. Journal of NeuroImmune Pharmacology, 2015, 10, 645-650.	4.1	36
208	URMC-099 facilitates amyloid-Î² clearance in a murine model of Alzheimerâ€™s disease. Journal of Neuroinflammation, 2018, 15, 137.	7.2	36
209	Bench-to-bedside translation of magnetic nanoparticles. Nanomedicine, 2014, 9, 501-16.	3.3	36
210	HIV-1 infected immune competent mononuclear phagocytes influence the pathways to neuronal demise. Neurotoxicity Research, 2001, 3, 461-484.	2.7	35
211	Immunopathogenesis of human immunodeficiency virus infection in the central nervous system. Annals of Neurology, 1988, 23, S78-S81.	5.3	34
212	Neuropathologic and neuroinflammatory activities of HIV-1-infected human astrocytes in murine brain. Glia, 2006, 54, 81-93.	4.9	34
213	Human Immunodeficiency Virus-Mononuclear Phagocyte Interactions:Emerging Avenues of Biomarker Discovery, Modes of Viral Persistence and Disease Pathogenesis. Current HIV Research, 2006, 4, 279-291.	0.5	34
214	AAV2/1 CD74 Gene Transfer Reduces Î²-amyloidosis and Improves Learning and Memory in a Mouse Model of Alzheimer's Disease. Molecular Therapy, 2015, 23, 1712-1721.	8.2	34
215	HIV-1-associated dementia: a basic science and clinical perspective. Aids Reader, 2002, 12, 358-68.	0.3	34
216	Diminished matrix metalloproteinase 9 secretion in human immunodeficiency virus-infected mononuclear phagocytes: modulation of innate immunity and implications for neurological disease. Journal of Neuroimmunology, 2004, 157, 11-16.	2.3	33

#	Article	IF	Citations
217	UPLCâ€“MS/MS quantification of nanoformulated ritonavir, indinavir, atazanavir, and efavirenz in mouse serum and tissues. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2011, 879, 2332-2338.	2.3	33
218	Opposing regulation of endolysosomal pathways by long-acting nanoformulated antiretroviral therapy and HIV-1 in human macrophages. Retrovirology, 2015, 12, 5.	2.0	33
219	Peripheral nerve induces macrophage neurotrophic activities: regulation of neuronal process outgrowth, intracellular signaling and synaptic function. Journal of Neuroimmunology, 2003, 142, 112-129.	2.3	32
220	A Synthetic Agonist to Vasoactive Intestinal Peptide Receptor-2 Induces Regulatory T Cell Neuroprotective Activities in Models of Parkinsonâ€™s Disease. Frontiers in Cellular Neuroscience, 2019, 13, 421.	3.7	32
221	Murine Models for Human Immunodeficiency Virus Type 1-Associated Dementia: The Development of New Treatment Testing Paradigms. Journal of NeuroVirology, 2002, 8, 49-52.	2.1	31
222	Molecular Characterization of a Putative Antiretroviral Transcriptional Factor, OTK18. Journal of Immunology, 2004, 172, 381-391.	0.8	31
223	Monocyte Differentiation, Activation, and Mycobacterial Killing Are Linked to Transsulfuration-dependent Redox Metabolism. Journal of Biological Chemistry, 2006, 281, 38712-38720.	3.4	31
224	Neuropathogenesis of human immunodeficiency virus infection. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2018, 152, 21-40.	1.8	31
225	HIV and the Macrophage: From Cell Reservoirs to Drug Delivery to Viral Eradication. Journal of NeuroImmune Pharmacology, 2019, 14, 52-67.	4.1	31
226	Combinatorial assessments of brain tissue metabolomics and histopathology in rodent models of human immunodeficiency virus infection. Journal of NeuroImmune Pharmacology, 2013, 8, 1224-1238.	4.1	30
227	Granulocyte-Macrophage Colony Stimulating Factor Exerts Protective and Immunomodulatory Effects in Cortical Trauma. Journal of Neuroimmunology, 2015, 278, 162-173.	2.3	30
228	Pharmacokinetics of a Long-Acting Nanoformulated Dolutegravir Prodrug in Rhesus Macaques. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	30
229	A Role for Extracellular Vesicles in SARS-CoV-2 Therapeutics and Prevention. Journal of NeuroImmune Pharmacology, 2021, 16, 270-288.	4.1	30
230	Dexamethasone Therapy Worsens the Neuropathology of Human Immunodeficiency Virus Type 1 Encephaliti in SCID Mice. Journal of Infectious Diseases, 1997, 175, 1368-1381.	4.0	29
231	Neuroprotective strategies for HIV-1 associated dementia. Neurotoxicity Research, 2004, 6, 503-521.	2.7	29
232	Proteomic fingerprints distinguish microglia, bone marrow, and spleen macrophage populations. Glia, 2005, 51, 161-172.	4.9	29
233	Functional Proteomic Analysis for Regulatory T Cell Surveillance of the HIV-1-Infected Macrophage. Journal of Proteome Research, 2010, 9, 6759-6773.	3.7	29
234	Pathways towards an effective immunotherapy for Parkinsonâ€™s disease. Expert Review of Neurotherapeutics, 2011, 11, 1703-1715.	2.8	29

#	Article	IF	Citations
235	The Promise of Long-Acting Antiretroviral Therapies: From Need to Manufacture. Trends in Microbiology, 2019, 27, 593-606.	7.7	29
236	Lipophilic nanocrystal prodrug-release defines the extended pharmacokinetic profiles of a year-long cabotegravir. Nature Communications, 2021, 12, 3453.	12.8	29
237	Brain ingress of regulatory T cells in a murine model of HIV-1 encephalitisâ˜†. Journal of Neuroimmunology, 2011, 230, 33-41.	2.3	28
238	Development of europium doped core-shell silica cobalt ferrite functionalized nanoparticles for magnetic resonance imaging. Acta Biomaterialia, 2017, 49, 507-520.	8.3	28
239	Design of mannosylated oral amphotericin B nanoformulation: efficacy and safety in visceral leishmaniasis. Artificial Cells, Nanomedicine and Biotechnology, 2018, 46, 521-531.	2.8	28
240	Defining the Innate Immune Responses for SARS-CoV-2-Human Macrophage Interactions. Frontiers in Immunology, 2021, 12, 741502.	4.8	28
241	Rapid and reliable quantitation of amino acids and myo-inositol in mouse brain by high performance liquid chromatography and tandem mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2012, 893-894, 15-20.	2.3	27
242	Can Humanized Mice Reflect the Complex Pathobiology of HIV-Associated Neurocognitive Disorders?. Journal of NeuroImmune Pharmacology, 2012, 7, 352-362.	4.1	27
243	The mixed lineage kinase-3 inhibitor URMC-099 improves therapeutic outcomes for long-acting antiretroviral therapy. Nanomedicine: Nanotechnology, Biology, and Medicine, 2016, 12, 109-122.	3.3	27
244	Bioimaging predictors of rilpivirine biodistribution and antiretroviral activities. Biomaterials, 2018, 185, 174-193.	11.4	27
245	Rod-shape theranostic nanoparticles facilitate antiretroviral drug biodistribution and activity in human immunodeficiency virus susceptible cells and tissues. Theranostics, 2020, 10, 630-656.	10.0	27
246	Macrophages, chemokines and neuronal injury in HIV-1-associated dementia. Cellular and Molecular Biology, 2002, 48, 137-50.	0.9	27
247	Mononuclear phagocyte biophysiology influences brain transendothelial and tissue migration: implication for HIV-1-associated dementia. Journal of Neuroimmunology, 2002, 122, 40-54.	2.3	26
248	Neuroinflammatory responses from microglia recovered from HIV-1-infected and seronegative subjects. Journal of Neuroimmunology, 2005, 163, 145-156.	2.3	26
249	Pharmacotoxicology of monocyte-macrophage nanoformulated antiretroviral drug uptake and carriage. Nanotoxicology, 2011, 5, 592-605.	3.0	26
250	Immunization strategies for Parkinson's disease. Parkinsonism and Related Disorders, 2012, 18, S218-S221.	2.2	26
251	Murine Motor and Behavior Functional Evaluations for Acute 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine (MPTP) Intoxication. Journal of NeuroImmune Pharmacology, 2012, 7, 279-288.	4.1	26
252	Granulocyte-macrophage colony-stimulating factor mRNA and Neuroprotective Immunity in Parkinson's disease. Biomaterials, 2021, 272, 120786.	11.4	26

#	Article	IF	Citations
253	Transformation of tenofovir into stable ProTide nanocrystals with long-acting pharmacokinetic profiles. Nature Communications, 2021, 12, 5458.	12.8	26
254	Effects of colony stimulating factors on the interaction of monocytes and the human immunodeficiency virus. Immunology Letters, 1988, 19, 193-198.	2.5	25
255	Infections of the nervous system. Lancet Neurology, The, 2005, 4, 12-13.	10.2	25
256	HIV-1 transforms the monocyte plasma membrane proteome. Cellular Immunology, 2009, 258, 44-58.	3.0	25
257	Control of neuroinflammation as a therapeutic strategy for amyotrophic lateral sclerosis and other neurodegenerative disorders. Experimental Neurology, 2010, 222, 1-5.	4.1	25
258	HIV Replication and Persistence in Human Gastrointestinal Cells Cultured In Vitro. Journal of Leukocyte Biology, 1991, 49, 499-504.	3.3	24
259	Development of a platelet-activating factor antagonist for HIV-1 associated neurocognitive disorders. Journal of Neuroimmunology, 2009, 213, 47-59.	2.3	24
260	Influence of age, irradiation and humanization on NSG mouse phenotypes. Biology Open, 2015, 4, 1243-1252.	1.2	24
261	Manganese-Enhanced Magnetic Resonance Imaging for Detection of Vasoactive Intestinal Peptide Receptor 2 Agonist Therapy in a Model of Parkinson's Disease. Neurotherapeutics, 2016, 13, 635-646.	4.4	24
262	A long acting nanoformulated lamivudine ProTide. Biomaterials, 2019, 223, 119476.	11.4	24
263	Unraveling the Mechanisms of Neurotoxicity in HIV Type 1-Associated Dementia: Inhibition of Neuronal Synaptic Transmission by Macrophage Secretory Products. AIDS Research and Human Retroviruses, 1999, 15, 57-63.	1.1	23
264	4-Aminopyridine Improves Spatial Memory in a Murine Model of HIV-1 Encephalitis. Journal of NeuroImmune Pharmacology, 2009, 4, 317-327.	4.1	23
265	Pharmacodynamics of folic acid receptor targeted antiretroviral nanotherapy in HIV-1-infected humanized mice. Antiviral Research, 2015, 120, 85-88.	4.1	23
266	Safety, tolerability, and immune-biomarker profiling for year-long sargramostim treatment of Parkinson's disease. EBioMedicine, 2021, 67, 103380.	6.1	23
267	CRISPR-Cas9 Mediated Exonic Disruption for HIV-1 Elimination. EBioMedicine, 2021, 73, 103678.	6.1	23
268	Proteomic analyses of monocytes obtained from Hispanic women with HIVâ€associated dementia show depressed antioxidants. Proteomics - Clinical Applications, 2010, 4, 706-714.	1.6	22
269	The mixed-lineage kinase 3 inhibitor URMC-099 facilitates microglial amyloid-Î² degradation. Journal of Neuroinflammation, 2016, 13, 184.	7.2	22
270	T cells and Parkinson's disease. Lancet Neurology, The, 2017, 16, 769-771.	10.2	22

#	Article	IF	Citations
271	Creation of a long-acting rilpivirine prodrug nanoformulation. Journal of Controlled Release, 2019, 311-312, 201-211.	9.9	22
272	Proteomic fingerprinting of human immunodeficiency virus type 1â€“associated dementia from patient monocyte-derived macrophages: A case study. Journal of NeuroVirology, 2004, 10, 74-81.	2.1	21
273	Plasma Proteomic Analysis of Simian Immunodeficiency Virus Infection of Rhesus Macaques. Journal of Proteome Research, 2010, 9, 4721-4731.	3.7	21
274	Pharmacokinetics, Biodistribution, and Toxicity of Folic Acid-Coated Antiretroviral Nanoformulations. Antimicrobial Agents and Chemotherapy, 2014, 58, 7510-7519.	3.2	21
275	Proteomic analysis of mesenchymal to Schwann cell transdifferentiation. Journal of Proteomics, 2017, 165, 93-101.	2.4	21
276	Optimizing the preparation and stability of decorated antiretroviral drug nanocrystals. Nanomedicine, 2018, 13, 871-885.	3.3	21
277	Oral antivirals for the prevention and treatment of SARS-CoV-2 infection. AIDS Reviews, 2022, 24, .	1.0	21
278	Transformation of dolutegravir into an ultra-long-acting parenteral prodrug formulation. Nature Communications, 2022, 13, .	12.8	21
279	Pulsed Stable Isotope Labeling of Amino Acids in Cell Culture Uncovers the Dynamic Interactions between HIV-1 and the Monocyte-Derived Macrophage. Journal of Proteome Research, 2011, 10, 2852-2862.	3.7	20
280	Functional Proteome of Macrophage Carried Nanoformulated Antiretroviral Therapy Demonstrates Enhanced Particle Carrying Capacity. Journal of Proteome Research, 2013, 12, 2282-2294.	3.7	20
281	Immune Activations and Viral Tissue Compartmentalization During Progressive HIV-1 Infection of Humanized Mice. Frontiers in Immunology, 2019, 10, 340.	4.8	20
282	Moving toward Tuberculosis Elimination. Critical Issues for Research in Diagnostics and Therapeutics for Tuberculosis Infection. American Journal of Respiratory and Critical Care Medicine, 2019, 199, 564-571.	5.6	20
283	Humanized Mice for Infectious and Neurodegenerative disorders. Retrovirology, 2021, 18, 13.	2.0	20
284	Proteomic fingerprinting of human immunodeficiency virus type 1?associated dementia from patient monocyte-derived macrophages: A case study. Journal of NeuroVirology, 2004, 10, 74-81.	2.1	19
285	Proteomic fingerprinting of HIV-1-infected human monocyte-derived macrophages: a preliminary report. Journal of Neuroimmunology, 2004, 147, 35-42.	2.3	19
286	OTK18 expression in brain mononuclear phagocytes parallels the severity of HIV-1 encephalitis. Journal of Neuroimmunology, 2004, 150, 186-198.	2.3	19
287	Development of a rapid autopsy program for studies of brain immunity. Journal of Neuroimmunology, 2005, 163, 135-144.	2.3	19
288	Glatiramer acetate immunization induces specific antibody and cytokine responses in ALS patients. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2007, 8, 235-242.	2.1	19

#	Article	IF	Citations
289	Plasma Proteomic Profiling in HIV-1 Infected Methamphetamine Abusers. PLoS ONE, 2012, 7, e31031.	2.5	19
290	Biodegradable polyanhydrideâ€based nanomedicines for blood to brain drug delivery. Journal of Biomedical Materials Research - Part A, 2018, 106, 2881-2890.	4.0	19
291	Modulation of innate immunity by copolymerâ€1 leads to neuroprotection in murine HIVâ€1 encephalitis. Glia, 2008, 56, 223-232.	4.9	18
292	Proteomic biosignatures for monocyteâ€“macrophage differentiation. Cellular Immunology, 2011, 271, 239-255.	3.0	18
293	Nanoformulated Antiretroviral Therapy Attenuates Brain Metabolic Oxidative Stress. Molecular Neurobiology, 2019, 56, 2896-2907.	4.0	18
294	Innate and acquired immunity in neurodegenerative disorders. Journal of Leukocyte Biology, 1999, 65, 407-408.	3.3	17
295	Proteomic fingerprinting of human immunodeficiency virus type 1-associated dementia from patient monocyte-derived macrophages: A case study. Journal of NeuroVirology, 2004, 10, 74-81.	2.1	17
296	Ingress of blood-borne macrophages across the blood-brain barrier in murine HIV-1 encephalitis. Journal of Neuroimmunology, 2008, 200, 41-52.	2.3	17
297	Methods Development for Blood Borne Macrophage Carriage of Nanoformulated Antiretroviral Drugs. Journal of Visualized Experiments, 2010, , .	0.3	17
298	Magnetic resonance imaging of folic acid-coated magnetite nanoparticles reflects tissue biodistribution of long-acting antiretroviral therapy. International Journal of Nanomedicine, 2015, 10, 3779.	6.7	17
299	ProTide generated long-acting abacavir nanoformulations. Chemical Communications, 2018, 54, 8371-8374.	4.1	17
300	Neuroprotective Activities of Long-Acting Granulocyteâ€“Macrophage Colony-Stimulating Factor (mPDM608) in 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Intoxicated Mice. Neurotherapeutics, 2020, 17, 1861-1877.	4.4	17
301	Fusobacterium necrophorum causing infective endocarditis and liver and splenic abscesses. Revista Do Instituto De Medicina Tropical De Sao Paulo, 2011, 53, 169-172.	1.1	16
302	Synthesis and characterization of a long-acting emtricitabine prodrug nanoformulation . International Journal of Nanomedicine, 2019, Volume 14, 6231-6247.	6.7	16
303	Rilpivirine-associated aggregation-induced emission enables cell-based nanoparticle tracking. Biomaterials, 2020, 231, 119669.	11.4	16
304	Europium-Doped Cerium Oxide Nanoparticles for Microglial Amyloid Beta Clearance and Homeostasis. ACS Chemical Neuroscience, 2022, 13, 1232-1244.	3.5	16
305	Activation of NR1a/NR2B receptors by monocyte-derived macrophage secretory products: implications for human immunodeficiency virus type one-associated dementia. Neuroscience Letters, 2003, 341, 246-250.	2.1	15
306	Adjunctive and long-acting nanoformulated antiretroviral therapies for HIV-associated neurocognitive disorders. Current Opinion in HIV and AIDS, 2014, 9, 585-590.	3.8	15

#	Article	IF	Citations
307	Presenilin-1 familial Alzheimerâ€™s disease mutation alters hippocampal neurogenesis and memory function in CCL2 null mice. Brain, Behavior, and Immunity, 2015, 49, 311-321.	4.1	15
308	Systemic HIV-1 infection produces a unique glial footprint in humanized mouse brains. DMM Disease Models and Mechanisms, 2017, 10, 1489-1502.	2.4	15
309	Synthesis of a long acting nanoformulated emtricitabine ProTide. Biomaterials, 2019, 222, 119441.	11.4	15
310	Regulation and Characterization of the Interferon-Î± Present in Patients with Advanced Human Immunodeficiency Virus Type 1 Disease. Journal of Interferon and Cytokine Research, 1996, 16, 127-137.	1.2	14
311	Pharmacokinetic interactions of CEP-1347 and atazanavir in HIV-infected patients. Journal of NeuroVirology, 2013, 19, 254-260.	2.1	14
312	Manganese-Enhanced Magnetic Resonance Imaging Reflects Brain Pathology During Progressive HIV-1 Infection of Humanized Mice. Molecular Neurobiology, 2016, 53, 3286-3297.	4.0	14
313	Biomarkers, Laboratory, and Animal Models for the Design and Development of Adjunctive Therapies for HIV-1 Dementia and other Neuroinflammatory Disorders. Journal of NeuroImmune Pharmacology, 2007, 2, 8-13.	4.1	13
314	Improved Visualization of Neuronal Injury Following Glial Activation by Manganese Enhanced MRI. Journal of NeuroImmune Pharmacology, 2013, 8, 1027-1036.	4.1	13
315	Enhancement of NMDA Receptor-Mediated Excitatory Postsynaptic Currents by gp120-Treated Macrophages: Implications for HIV-1-Associated Neuropathology. Journal of NeuroImmune Pharmacology, 2013, 8, 921-933.	4.1	13
316	Mouse brain fixation to preserve In vivo manganese enhancement for ex vivo manganeseâ€enhanced MRI. Journal of Magnetic Resonance Imaging, 2013, 38, 482-487.	3.4	13
317	Cellular Responses and Tissue Depots for Nanoformulated Antiretroviral Therapy. PLoS ONE, 2015, 10, e0145966.	2.5	13
318	Simultaneous quantification of intracellular lamivudine and abacavir triphosphate metabolites by LCâ€“MS/MS. Journal of Pharmaceutical and Biomedical Analysis, 2018, 153, 248-259.	2.8	13
319	The promise of nanoneuromedicine. Nanomedicine, 2014, 9, 171-176.	3.3	12
320	Pathways towards human immunodeficiency virus elimination. EBioMedicine, 2020, 53, 102667.	6.1	12
321	A long-acting 3TC ProTide nanoformulation suppresses HBV replication in humanized mice. Nanomedicine: Nanotechnology, Biology, and Medicine, 2020, 28, 102185.	3.3	12
322	Dolutegravir Inhibition of Matrix Metalloproteinases Affects Mouse Neurodevelopment. Molecular Neurobiology, 2021, 58, 5703-5721.	4.0	12
323	Utility of cerebral proton magnetic resonance spectroscopy in differential diagnosis of HIV-related dementia. Journal of NeuroVirology, 1995, 1, 268-274.	2.1	11
324	The neuropathogenesis of HIVâ€1 infection. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2007, 85, 45-67.	1.8	11

#	Article	IF	Citations
325	Rebuilding Synaptic Architecture in HIV-1 Associated Neurocognitive Disease: A Therapeutic Strategy Based on Modulation of Mixed Lineage Kinase. Neurotherapeutics, 2010, 7, 392-398.	4.4	11
326	Small magnetite antiretroviral therapeutic nanoparticle probes for MRI of drug biodistribution. Nanomedicine, 2014, 9, 1341-1352.	3.3	11
327	Persistent EcoHIV infection induces nigral degeneration in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-intoxicated mice. Journal of NeuroVirology, 2018, 24, 398-410.	2.1	11
328	Synthesis and Characterization of Long-Acting Darunavir Prodrugs. Molecular Pharmaceutics, 2020, 17, 155-166.	4.6	11
329	Ultra-long-acting (XLA) antivirals for chronic viral hepatitis. International Journal of Infectious Diseases, 2022, 114, 45-50.	3.3	11
330	Monocyte biomarkers define sargramostim treatment outcomes for Parkinson's disease. Clinical and Translational Medicine, 2022, 12, .	4.0	11
331	The Promise and Perils of CNS Drug Delivery: A Video Debate. Journal of NeuroImmune Pharmacology, 2008, 3, 58-58.	4.1	10
332	Changes in the plasma proteome follows chronic opiate administration in simian immunodeficiency virus infected rhesus macaques. Drug and Alcohol Dependence, 2012, 120, 105-112.	3.2	10
333	Neuropharmacologic Approaches to Restore the Brainâ€™s Microenvironment. Journal of NeuroImmune Pharmacology, 2016, 11, 484-494.	4.1	10
334	Development of an extended half-life GM-CSF fusion protein for Parkinson's disease. Journal of Controlled Release, 2022, 348, 951-965.	9.9	10
335	Regulation of Cytokine and Viral Gene Expression in Monocytes Infected with the Human Immunodeficiency Virus. Pathobiology, 1991, 59, 209-213.	3.8	9
336	BL-1023 improves behavior and neuronal survival in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-intoxicated mice. Neuroscience, 2011, 180, 293-304.	2.3	9
337	Antiretroviral Drug Metabolism in Humanized PXR-CAR-CYP3A-NOG Mice. Journal of Pharmacology and Experimental Therapeutics, 2018, 365, 272-280.	2.5	9
338	Modulating cellular autophagy for controlled antiretroviral drug release. Nanomedicine, 2018, 13, 2139-2154.	3.3	9
339	The Immunopathobiology of SARS-CoV-2 Infection. FEMS Microbiology Reviews, 2021, 45, .	8.6	9
340	The Neuropathogenesis of HIV-1 Infection. , 2004, , 95-115.		8
341	Pharmacokinetic testing of a first-generation cabotegravir prodrug in rhesus macaques. Aids, 2019, 33, 585-588.	2.2	8
342	Commentary: Animal Models of NeuroAIDS. Journal of NeuroImmune Pharmacology, 2012, 7, 301-305.	4.1	7

#	Article	IF	Citations
343	Broad-spectrum antivirals. Nature Materials, 2018, 17, 114-116.	27.5	7
344	Amplification of Replication Competent HIV-1 by Adoptive Transfer of Human Cells From Infected Humanized Mice. Frontiers in Cellular and Infection Microbiology, 2020, 10, 38.	3.9	7
345	Recovery of Latent HIV-1 from Brain Tissue by Adoptive Cell Transfer in Virally Suppressed Humanized Mice. Journal of NeuroImmune Pharmacology, 2021, 16, 796-805.	4.1	7
346	MEMRI is a biomarker defining nicotine-specific neuronal responses in subregions of the rodent brain. American Journal of Translational Research (discontinued), 2017, 9, 601-610.	0.0	7
347	Methods for Isolation and Identification of Nanoparticle-Containing Subcellular Compartments. Methods in Molecular Biology, 2013, 991, 47-55.	0.9	6
348	Broad Spectrum Mixed Lineage Kinase Type 3 Inhibition and HIV-1 Persistence in Macrophages. Journal of NeuroImmune Pharmacology, 2019, 14, 44-51.	4.1	6
349	Ultra-long-acting antivirals as chemical vaccines to prevent viral diseases. Future Microbiology, 2022, 17, 887-897.	2.0	6
350	Registration of in vivo MR to histology of rodent brains using blockface imaging. Proceedings of SPIE, 2009, , .	0.8	5
351	Immunoisolation of Nanoparticles Containing Endocytic Vesicles for Drug Quantitation. Methods in Molecular Biology, 2013, 991, 41-46.	0.9	5
352	HIV-1-Associated Left Ventricular Cardiac Dysfunction in Humanized Mice. Scientific Reports, 2020, 10, 9746.	3.3	5
353	Molecular pathogenesis of human immunodeficiency virus infection. Gene Analysis Techniques, 1988, 5, 41-53.	1.0	4
354	Model Systems for Assessing Cognitive Function: Implications for HIV-1 Infection and Drugs of Abuse. , 2001, 493, 7-27.		4
355	Predictive biomarkers for cognitive decline during progressive HIV infection. EBioMedicine, 2020, 51, 102538.	6.1	4
356	Efavirenz, atazanavir, and ritonavir disrupt sarcoplasmic reticulum Ca2+ homeostasis in skeletal muscles. Antiviral Research, 2021, 187, 104975.	4.1	4
357	Pharmacotherapeutics of SARS-CoV-2 Infections. Journal of NeuroImmune Pharmacology, 2021, 16, 12-37.	4.1	4
358	The blood-brain barrier: a defensive shield or a perpetrator of microbial invasion?. Journal of NeuroVirology, 1999, 5, 533-537.	2.1	3
359	Levels of human immunodeficiency virus type 1 (HIV-1) replication in macrophages determines the severity of murine HIV-1 encephalitis. Journal of NeuroVirology, 2004, 10, 82-90.	2.1	3
360	Registered Bioimaging of Nanomaterials for Diagnostic and Therapeutic Monitoring. Journal of Visualized Experiments, 2010, , .	0.3	3

#	Article	IF	Citations
361	Pathways Toward a Functional HIV-1 Cure: Balancing Promise and Perils of CRISPR Therapy. Methods in Molecular Biology, 2022, 2407, 429-445.	0.9	3
362	Prodrug Therapies for Infectious and Neurodegenerative Diseases. Pharmaceutics, 2022, 14, 518.	4.5	3
363	A Link Between Methylglyoxal and Heart Failure During HIV-1 Infection. Frontiers in Cardiovascular Medicine, 2021, 8, 792180.	2.4	3
364	Interleukin-2 expands neuroprotective regulatory T cells in Parkinsonâ€™s disease. , 2022, .		3
365	Neuroimaging and Proteomic Tracking of Neurodegeneration in MPTPâ€Treated Mice. Annals of the New York Academy of Sciences, 2003, 991, 319-321.	3.8	2
366	Not Just Another Jigsaw Puzzle. Journal of NeuroImmune Pharmacology, 2012, 7, 1-2.	4.1	2
367	Lipids and cognition make good bedfellows for neuroAIDS. Neurology, 2013, 81, 1480-1481.	1.1	2
368	Fourth Annual Conference of the American Society for Nanomedicine. Journal of NeuroImmune Pharmacology, 2014, 9, 1-38.	4.1	2
369	Potential of N-acetylated-para-aminosalicylic acid to accelerate manganese enhancement decline for long-term MEMRI in rodent brain. Journal of Neuroscience Methods, 2015, 251, 92-98.	2.5	2
370	Generation and Disease Model Relevance of a Manganese Enhanced Magnetic Resonance Imaging-Based NOD/scid-IL-2RÎ³ c null Mouse Brain Atlas. Journal of NeuroImmune Pharmacology, 2016, 11, 133-141.	4.1	2
371	Chemical exchange saturation transfer for detection of antiretroviral drugs in brain tissue. Aids, 2021, 35, 1733-1741.	2.2	2
372	Non-neuronal interactions in HIV-1-associated dementia. Advances in Molecular and Cell Biology, 2003, 31, 901-920.	0.1	1
373	Chemokines and Their Receptors and the Neuropathogenesis of HIV-1 Infection. , 2006, , 45-80.		1
374	Macrophages, Microglia, and Dendritic C. , 2008, , 89-104.		1
375	P-D5 Synthesis and characterization of core-â€“shell silica cobalt ferrite nanoparticles as a first step towards developing ultrasensitive MRI probes for long-acting antiretroviral drug biodistribution testing. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 74, 91.	2.1	1
376	Immunotherapies for Movement Disorders: Parkinsonâ€™s Disease and Amyotrophic Lateral Sclerosis. , 2017, , 767-797.		1
377	P1â€025: EXOSOMES CONTAINING SPECIFIC TAU OLIGOMER FORMATIONS ACCELERATE PATHOLOGICAL TAU PHOSPHORYLATION IN C57BL/6 MICE. Alzheimer's and Dementia, 2018, 14, P275.	0.8	1
378	O2â€01â€02: CHARACTERIZATION OF HUMAN ALZHEIMER'S DISEASE BRAINâ€DERIVED EXOSOMES. Alzheimer's and Dementia, 2018, 14, P608.	0.8	1

#	Article	IF	Citations
379	In Appreciation for a Job Well Done!. Journal of NeuroImmune Pharmacology, 2019, 14, 1-1.	4.1	1
380	J-109â€ƒSequential administration of LASER ART and CRISPR-Cas9 can facilitate HIV-1 elimination in humanized mice. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 81, 55-55.	2.1	1
381	Elucidating the pathogenic mechanisms of AD brainâ€derived, tauâ€containing extracellular vesicles: Highly transmissible and preferential propagation to GABAergic neurons. Alzheimer's and Dementia, 2020, 16, e037316.	0.8	1
382	Long-Acting Nanoformulated Antiretroviral Therapy. , 2016, , 1-10.		1
383	Neural Immunity and Human Immunodeficiency Virus-1-Associated Dementia. , 2004, , 547-559.		1
384	Centrifugal Elutriation for Studies of Neuroimmunity. Springer Protocols, 2014, , 165-175.	0.3	1
385	Chemokines and the Neuropathogenesis of HIV-1 Infection. , 0, , 151-171.		1
386	The COVID-19 Pandemic: Reflections of Science, Person, and Challenge in Academic Research Settings. Journal of NeuroImmune Pharmacology, 2021, 16, 706-717.	4.1	1
387	Development of an in Vitro Human Monocyte-Derived Macrophage-Based System for Drug Screening against HIV-1. Annals of the New York Academy of Sciences, 1990, 616, 597-598.	3.8	0
388	The Journal of Neuroimmune Pharmacology Reaches Its Stride. Journal of NeuroImmune Pharmacology, 2007, 2, 129-130.	4.1	0
389	Opendra â€œBillâ€•Narayan (1936â€“2007): A Personal Tribute to a Friend, Teacher, and Colleague. Journal of NeuroImmune Pharmacology, 2008, 3, 1-4.	4.1	0
390	Disseminating Research Discovery Through an Interactive Video: a Paradigm Shift for Journal Publication. Journal of NeuroImmune Pharmacology, 2008, 3, 57-57.	4.1	0
391	Erratum to â€œCSF proteomic fingerprints for HIV-associated cognitive impairmentâ€• Journal of Neuroimmunology, 2008, 205, 161.	2.3	0
392	Introducing Neuroimmune Pharmacology. , 2008, , 1-3.		0
393	Neuroprotective Activities of CD4+CD25+ Regulatory T Cells. NeuroImmune Biology, 2010, 9, 197-210.	0.2	0
394	Change in Evolution. Journal of NeuroImmune Pharmacology, 2012, 7, 715-716.	4.1	0
395	Control of Neuroinflammation for Therapeutic Gain. , 2017, , 971-978.		0
396	Overview of Mononuclear Phagocytes. , 2017, , 141-153.		0

#	Article	IF	Citations
397	Macrophages, Microglia and Dendritic Cell Function. , 2017, , 155-166.		0
398	Thank You!. Journal of NeuroImmune Pharmacology, 2017, 12, 565-565.	4.1	0
399	P-A9 Transformation of Darunavir into a long acting nanoformulated prodrug. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 77, 55-55.	2.1	0
400	P-A8 Establishing tissue reservoirs for the human immunodeficiency virus in humanized mice. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 77, 55-55.	2.1	0
401	D-110 Synergism between CRISPR/Cas9 and LASER ART leads to elimination of HIV-1 with no rebound in Humanized Mice. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 77, 42-42.	2.1	0
402	Europium sulfide nanoprobes predict antiretroviral drug delivery into HIV-1 cell and tissue reservoirs. Nanotheranostics, 2021, 5, 417-430.	5.2	0
403	Neuroimmune Cross Talk and HIV-Associated Neurocognitive Disorders. , 2013, , 211-248.		0
404	Neuronanomedicine. Springer Protocols, 2014, , 223-231.	0.3	0
405	Cell-Based Drug Delivery for Improving Antiretroviral Therapeutic Outcomes. , 2014, , 529-546.		0
406	Nanomedicines for Nervous System Diseases. , 2014, , 2125-2156.		0
407	Long-Acting Nanoformulated Antiretroviral Therapy. , 2018, , 1211-1220.		0
408	JNIP Impact Factor Rise Is a Final Tribute to the Years of Impactful Service Made by our Managing Editor. Journal of NeuroImmune Pharmacology, 2020, 15, 341-342.	4.1	0
409	Neuroprotective Immunity for Neurodegenerative and Neuroinfectious Diseases. , 2020, , 335-370.		0
410	CD4+ T cell effector activities accelerate Alzheimer's disease pathologies.. Alzheimer's and Dementia, 2021, 17 Suppl 3, e052738.	0.8	0